Polk County’s level of immunization for kindergartners dropped from 96.3% in 2021 to 93.2% in 2023, still above the statewide ...

As of market close on Friday, Jan. 24, Moderna stock is up 21.6% this week. Here's why.

Norovirus cases are significantly increasing in the US and Canada. Moderna is developing an mRNA-based vaccine, currently in ...

Based on its share price, down 75% in the last three years, it's easy to write off Moderna (NASDAQ: MRNA) as a biotech ...

While drugmakers are hard at work on the shots, they’re not yet ready to blunt the impact of a potential pandemic.

Moderna is developing an mRNA-based vaccine for norovirus, now in Phase 3 trials, with hopes of approval by 2026 to combat the highly contagious stomach virus.

The Stargate Initiative, spearheaded by several tech giants, has raised alarm in the most paranoid parts of the MAGA movement ...

Traditional vaccines typically focus on the most accessible parts of viruses, which are often the rapidly mutating ...

Moderna provided an update on the status of its trial investigating a vaccine candidate for norovirus in a company statement on Monday.

The press release also contained forward-looking statements, cautioning that these are not guarantees and are subject to risks, uncertainties, and other factors that could cause actual results to ...

Under the agreement, 17 participating countries could order an updated version of the biotech company's mRNA Covid-19 vaccine for up to four years. The vaccine, marketed as Spikevax in Europe, was ...

Moderna (MRNA) stock gained in the premarket after the company received a tender to supply its COVID-19 vaccine in the EU, ...